Drugs.com - Monthly Update October 2025

This month’s update dives into significant FDA approvals affecting key therapeutic areas. Discover groundbreaking treatments like Novo Nordisk’s Rybelsus for cardiovascular risk reduction in diabetes, and innovative solutions like Gazyva for lupus nephritis. Tune in to learn how these advancements could impact patient management and outcomes.Rybelsus (semaglutide): Exploring its new role in cardiovascular risk reduction for adults with type 2 diabetes.Zoryve (roflumilast): A breakthrough steroid-free topical treatment for eczema in young children.Gazyva (obinutuzumab): Approved for lupus nephritis, offering new hope for managing this serious kidney ailment.Lynkuet (elinzanetant): A hormone-free option for alleviating hot flashes due to menopause.Lasix ONYU (furosemide injection): Introducing an at-home infusion method for heart failure patients dealing with edema.Jascayd (nerandomilast): A new approval to combat the progression of idiopathic pulmonary fibrosis.Chapters:(00:00) - Intro (00:40) - Rybelsus (01:36) - Zoryve Cream (02:17) - Gazyva (02:51) - Lynkuet (03:01) - Lasix ONYU (03:44) - Jascayd (04:16) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app